ProCE Banner Activity

Where Might Investigational Long-Acting 2-Drug Combinations of ARVs With Novel Mechanisms of Action Fit Into the Future HIV Treatment Landscape?

Clinical Thought
Thoughts on how investigational, long-acting 2-drug regimens involving drugs with novel mechanisms of action may expand treatment options not only for treatment-experienced patients, but also for ART-naive patients in key populations with specific needs.

Released: November 30, 2021

Expiration: November 29, 2022

Share

Faculty

Karine Lacombe

Karine Lacombe, MD, PhD

Professor of Medicine
Infectious Diseases Department
Sorbonne Uiversité
Inserm Pierre Louis School of Public Health
Paris, France

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Educational grant provided by

Merck Sharp & Dohme Corp.

ViiV Healthcare

Faculty Disclosure

Primary Author

Karine Lacombe, MD, PhD

Professor of Medicine
Infectious Diseases Department
Sorbonne Uiversité
Inserm Pierre Louis School of Public Health
Paris, France

Karine Lacombe, MD, PhD, has disclosed that she has received consulting fees from AbbVie, Chiesi, Gilead Sciences, and Janssen.